GlassScriptPhysician profile
Ashwin A Patkar
NPI 1376627265
$103,166.96
in general payments reported to CMS, 2019-2025
47 companies · $4,231 in 2025
The $4,231 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56K · 2020: $26K · 2021: $6,627 · 2022: $4,363 · 2023: $3,770 · 2024: $3,070 · 2025: $4,231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,071.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $38,334.18 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $37,873.28 | 2019-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Mdd US Operations, LLC | $5,612.21 | 2019 | |
| Indivior INC. | $4,084.97 | 2020-2025 | Sublocade |
| Abbvie INC. | $3,231.90 | 2021-2025 | |
| Sage Therapeutics, LLC | $2,631.31 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,614.08 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $1,301.70 | 2019-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $840.87 | 2022-2025 | Sunosi, Auvelity |
| Teva Pharmaceuticals USA, INC. | $807.24 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Alkermes, INC. | $789.26 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $692.57 | 2021-2025 | Rexulti, Vyepti |
| Supernus Pharmaceuticals, INC. | $585.85 | 2022-2024 | Qelbree, Qelbree |
| Jazz Pharmaceuticals INC. | $573.54 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $492.09 | 2019-2022 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $468.24 | 2021-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $388.03 | 2021-2025 | Fanapt, Hetlioz |
| Bausch Health US, LLC | $318.27 | 2021-2025 | Aplenzin, Wellbutrin |
| Corium, LLC | $305.08 | 2021-2023 | Azstarys |
| Livanova USA, INC. | $287.98 | 2024-2025 | Vns Therapy Symmetry Model 8103 Generator |
| E.R. Squibb & Sons, L.L.C. | $258.94 | 2024-2025 | Cobenfy |
| Tris Pharma INC | $232.13 | 2022-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $208.76 | 2022-2024 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $171.42 | 2023-2024 | Quviviq |
| Allergan, INC. | $118.91 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $118.12 | 2021-2023 | Belsomra |
| Collegium Pharmaceutical, INC. | $97.33 | 2023-2025 | Jornay Pm, Belbuca |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $87.50 | 2019 | |
| Uswm, LLC | $68.94 | 2021 | |
| Amgen INC. | $66.45 | 2022 | |
| Neos Therapeutics, LP | $63.77 | 2022-2023 | Adzenys Xr-Odt |
| Avanir Pharmaceuticals, INC. | $59.21 | 2022 | |
| Lilly USA, LLC | $42.07 | 2025 | Zepbound |
| Braeburn INC. | $39.71 | 2025 | Brixadi |
| Brainsway USA INC | $34.60 | 2021-2022 | |
| Averitas Pharma INC. | $29.99 | 2023 | Qutenza |
| Acadia Pharmaceuticals INC | $29.41 | 2020 | |
| Abbott Laboratories | $28.31 | 2024 | Eterna |
| Viiv Healthcare Company | $26.98 | 2024 | Apretude |
| Biogen, INC. | $24.15 | 2025 | Zurzuvae |
| Almatica Pharma LLC | $22.68 | 2022 | |
| Hikma Pharmaceuticals USA | $21.84 | 2022 | |
| Grt US Holding, INC. | $18.64 | 2022 | |
| Luye Pharma (USA) LTD. | $18.23 | 2025 | Erzofri Extended-Release |
| Noven Therapeutics, LLC | $16.94 | 2024 | Xelstrym |
| Scilex Pharmaceuticals INC. | $15.30 | 2022 | |
| Aytu Biopharma, INC. | $13.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashwin Patkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.